[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dermavon Holdings Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100628705","phase-2-a-multicenter-randomized-double-blind-placebo-controlled-phase--clinical-study-to-evaluate-the-efficacy-and-safety-of-cms-d001-in-adult-patients-with-moderate-to-severe-atopic-dermatitis-100628705",false,"NCT07465120","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis","Inclusion Criteria:\n\n* Aged 18-75 years, willing to sign the ICF\n* Clinical diagnosis of AD (Hanifin \\& Rajka criteria) for ≥1 year\n* At screening and baseline, EASI score ≥ 16 points, IGA ≥ 3, BSA ≥ 10%, Itch NRS ≥ 4\n* Documented history of inadequate response to topical corticosteroids (TCS) or -topical calcineurin inhibitors (TCI).\n* Subject has applied a topical emollient (moisturizer) daily for at least 7 days prior to the Baseline Visit.\n\nExclusion Criteria:\n\n* Other active skin conditions that may interfere with AD assessment.\n* History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose.\n* History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose.\n* Active infection or acute illness within 7 days prior to the first dose.\n* Chronic or recurrent infectious diseases at screening or baseline that may increase safety risks.\n* Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.\n* History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation.\n* History of malignant tumour within 5 years before screening.\n* Previous or current autoimmune diseases.\n* Positive results of confirmatory test for hepatitis B, hepatitis C, human\n* immunodeficiency virus (HIV) or syphilis.\n* Allergic to any component of the investigational drug.","ALL","18 Years","75 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy, safety, and tolerability of CMS-D001 in participants with moderate to severe atopic dermatitis, as well as to assess the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of CMS-D001 and its major metabolites (as applicable) in participants with moderate to severe atopic dermatitis, so as to provide a basis for the dosage of the Phase III confirmatory clinical trial.",[26],"Moderate to Severe Atopic Dermatitis","NOT_YET_RECRUITING","2026-03-08",{"date":30,"type":31},"2026-03-11","ACTUAL",{"date":33,"type":20},"2026-03-20",{"date":35,"type":20},"2027-05-31",{"name":37,"class":38},"Dermavon Holdings Limited","INDUSTRY",28,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":62},"100626224","phase-2-a-clinical-study-evaluating-the-efficacy-and-safety-of-cms-d001-tablets-in-the-treatment-of-adult-patients-with-moderate-to-severe-plaque-type-psoriasis-100626224","NCT07432854","A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ\u002FⅢ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Aged 18-75 years, willing to sign the ICF\n* Diagnosed with plaque psoriasis for at least 6 months prior to screening.\n* At screening and baseline, PASI score ≥ 12 points, BSA ≥ 10%, sPGA ≥ 3\n* Be eligible for phototherapy or systemic therapy.\n\nExclusion Criteria:\n\n* Non-plaque psoriasis (ie, guttate, pustular, erythrodermic, or inverse psoriasis) within 3 months prior to baseline.\n* Other skin diseases at screening or baseline Drug-induced psoriasis.\n* History of severe herpes zoster or severe herpes simplex or current herpes simplex\u002Fzoster infection.\n* History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose.\n* History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose.\n* Active infection or acute illness within 7 days prior to the first dose. Chronic or recurrent infectious diseases at screening or baseline that, in the investigator's judgment, may increase safety risks.\n* Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.\n* History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation.\n* History of malignant tumour within 5 years before screening.\n* Previous or current autoimmune diseases.\n* Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis.\n* Allergic to any component of the investigational drug.",{"count":48,"type":20},540,[23,50],"PHASE3","This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II\u002FIII operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.",[53],"Moderate to Severe Plaque Psoriasis","2026-02-24",{"date":56,"type":31},"2026-02-25",{"date":58,"type":20},"2026-03-03",{"date":60,"type":20},"2028-07-30",{"name":37,"class":38},21,""]